Atlas Trials

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

Clinical trial NCT04572308 · COMPLETED

Trial details

NCT number
NCT04572308
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Start date
2020-10-01
Primary completion
2021-05-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.